Literature DB >> 22004976

The association between interleukin-6 polymorphisms and systemic lupus erythematosus: a meta-analysis.

Y H Lee1, H S Lee, S J Choi, J D Ji, G G Song.   

Abstract

The aim of this study was to determine whether the functional interleukin-6 (IL-6) promoter -174 G/C and -572 G/C polymorphisms confer susceptibility to systemic lupus erythematosus (SLE) in ethnically different populations. Meta-analysis was conducted on the associations between the IL-6 polymorphisms and SLE using; 1) allele contrast, 2) the recessive model, 3) the dominant model, and 4) the additive model. A total of 11 studies were considered in this study, and ethnicity-specific meta-analysis was performed on European and Asian populations. Meta-analysis of the IL-6 -174 G/C polymorphism showed an association between SLE and the IL-6 -174 G allele in all study subjects (odds ratio (OR) = 1.344, 95% confidence interval (CI) = 1.052-1.718, p = 0.018). Furthermore, stratification by ethnicity indicated an association between the IL-6 -174 G allele and SLE in Europeans (OR = 1.264, 95% CI = 1.037-1.541, p = 0.020). Meta-analysis of the IL-6 -572 G/C polymorphism revealed that an association was found between SLE and the IL-6 -572 G/C polymorphism using the recessive model, but ethnicity-specific meta-analysis revealed no association between SLE and the IL-6 -572 G/C polymorphism in Asians. In conclusion, this meta-analysis demonstrates that the IL-6 -174 G/C polymorphism may confer susceptibility to SLE in Europeans, but that the IL-6 -572 G/C polymorphism is not associated with susceptibility to SLE in Asians.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22004976     DOI: 10.1177/0961203311422711

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  9 in total

1.  Association between tumor necrosis factor-α promoter -308 A/G, -238 A/G, interleukin-6 -174 G/C and -572 G/C polymorphisms and periodontal disease: a meta-analysis.

Authors:  Gwan Gyu Song; Sung Jae Choi; Jong Dae Ji; Young Ho Lee
Journal:  Mol Biol Rep       Date:  2013-05-09       Impact factor: 2.316

Review 2.  A meta-analysis of the association of IL-6 -174 G/C and -572 G/C polymorphisms with systemic lupus erythematosus risk.

Authors:  Zaixing Yang; Yan Liang; Baodong Qin; Renqian Zhong
Journal:  Rheumatol Int       Date:  2013-09-07       Impact factor: 2.631

Review 3.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

4.  TGF-β1 limits the onset of innate lung inflammation by promoting mast cell-derived IL-6.

Authors:  Kirthana Ganeshan; Laura K Johnston; Paul J Bryce
Journal:  J Immunol       Date:  2013-04-29       Impact factor: 5.422

Review 5.  Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update.

Authors:  Hua Su; Chun-Tao Lei; Chun Zhang
Journal:  Front Immunol       Date:  2017-04-21       Impact factor: 7.561

6.  IL-1β and IL-6 Are Highly Expressed in RF+IgE+ Systemic Lupus Erythematous Subtype.

Authors:  Yongkang Wu; Bei Cai; Junlong Zhang; Beilei Shen; Zhuochun Huang; Chunyu Tan; Carla C Baan; Lanlan Wang
Journal:  J Immunol Res       Date:  2017-02-12       Impact factor: 4.818

7.  Relationship Between Interleukin-6 -174G/C Genetic Variant and Efficacy of Methotrexate Treatment in Psoriatic Arthritis Patients.

Authors:  Renata Sokolik; Milena Iwaszko; Jerzy Świerkot; Barbara Wysoczańska; Lucyna Korman; Piotr Wiland; Katarzyna Bogunia-Kubik
Journal:  Pharmgenomics Pers Med       Date:  2021-01-28

Review 8.  The role of type 1 interferon in systemic sclerosis.

Authors:  Minghua Wu; Shervin Assassi
Journal:  Front Immunol       Date:  2013-09-06       Impact factor: 7.561

9.  Role of the promoter polymorphism IL-6 -174G/C in dermatomyositis and systemic lupus erythematosus.

Authors:  Maria Hristova; Lyubomir Dourmishev; Zornitsa Kamenarska; Svetla Nikolova; Radka Kaneva; Anton Vinkov; Marta Baleva; Daniela Monova; Vanio Mitev
Journal:  Biomed Res Int       Date:  2013-09-11       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.